» Authors » Punit P Seth

Punit P Seth

Explore the profile of Punit P Seth including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 109
Citations 3064
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Prakash T, Yu J, Shen W, De Hoyos C, Berdeja A, Gaus H, et al.
ACS Med Chem Lett . 2021 Jun; 12(6):922-927. PMID: 34141070
Site-specific incorporation of 2'-modifications and neutral linkages in the deoxynucleotide gap region of toxic phosphorothioate (PS) gapmer ASOs can enhance therapeutic index and safety. In this manuscript, we determined the...
12.
Gokirmak T, Nikan M, Wiechmann S, Prakash T, Tanowitz M, Seth P
Trends Pharmacol Sci . 2021 May; 42(7):588-604. PMID: 34020790
Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by...
13.
Knerr L, Prakash T, Lee R, Iii W, Nikan M, Fu W, et al.
J Am Chem Soc . 2021 Feb; 143(9):3416-3429. PMID: 33626278
The extra hepatic delivery of antisense oligonucleotides (ASOs) remains a challenge and hampers the widespread application of this powerful class of therapeutic agents. In that regard, pancreatic beta cells are...
14.
Vasquez G, Freestone G, Wan W, Low A, De Hoyos C, Yu J, et al.
Nucleic Acids Res . 2021 Feb; 49(4):1828-1839. PMID: 33544849
We recently showed that site-specific incorporation of 2'-modifications or neutral linkages in the oligo-deoxynucleotide gap region of toxic phosphorothioate (PS) gapmer ASOs can enhance therapeutic index and safety. In this...
15.
Asami Y, Nagata T, Yoshioka K, Kunieda T, Yoshida-Tanaka K, Bennett C, et al.
Mol Ther . 2020 Dec; 29(2):838-847. PMID: 33290725
We recently reported the antisense properties of a DNA/RNA heteroduplex oligonucleotide consisting of a phosphorothioate DNA-gapmer antisense oligonucleotide (ASO) strand and its complementary phosphodiester RNA/phosphorothioate 2'-O-methyl RNA strand. When α-tocopherol...
16.
He C, Migawa M, Chen K, Weston T, Tanowitz M, Song W, et al.
Nucleic Acids Res . 2020 Dec; 49(1):1-14. PMID: 33275144
Nucleic acid therapeutics (NATs) have proven useful in promoting the degradation of specific transcripts, modifying gene expression, and regulating mRNA splicing. In each situation, efficient delivery of nucleic acids to...
17.
Hyjek-Skladanowska M, Stasinska A, Napiorkowska-Gromadzka A, Bartlomiejczak A, Seth P, Chmielewski M, et al.
Bioorg Med Chem . 2020 Sep; 28(23):115741. PMID: 32992250
The chemical cross-linking of complexes of proteins with nucleic acids is often used in structural and mechanistic studies of these oftentimes unstable and transient complexes. To date, no method has...
18.
Crooke S, Seth P, Vickers T, Liang X
J Am Chem Soc . 2020 Aug; 142(35):14754-14771. PMID: 32786803
Recent progress in understanding phosphorothioate antisense oligonucleotide (PS-ASO) interactions with proteins has revealed that proteins play deterministic roles in the absorption, distribution, cellular uptake, subcellular distribution, molecular mechanisms of action,...
19.
Nikan M, Tanowitz M, Dwyer C, Jackson M, Gaus H, Swayze E, et al.
J Med Chem . 2020 Jul; 63(15):8471-8484. PMID: 32677436
Despite recent advances, targeted delivery of therapeutic oligonucleotide to extra-hepatic tissues continues to be a challenging endeavor and efficient ligand-receptor systems need to be identified. To determine the feasibility of...
20.
Vickers T, Migawa M, Seth P, Crooke S
J Am Chem Soc . 2020 May; 142(21):9661-9674. PMID: 32374993
The activity of PS-ASOs is strongly influenced by association with both inter- and intracellular proteins. The sequence, chemical nature, and structure of the ASO can have profound influences on the...